Alan Rong
Overview
Explore the profile of Alan Rong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
1556
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Takeda K, Hashimoto A, Liu S, Rong A
J Biopharm Stat
. 2024 Feb;
35(2):271-282.
PMID: 38369872
It is well known a basket trial consisting of multiple cancer types has the potential of borrowing strength across the baskets defined by the cancer types, leading to an efficient...
2.
Li R, Takeda K, Rong A
Ther Innov Regul Sci
. 2023 Apr;
57(4):728-736.
PMID: 37087525
It has become quite common in recent early oncology trials to include both the dose-finding and the dose-expansion parts within the same study. This shift can be viewed as a...
3.
Liu S, Takeda K, Rong A
Pharm Stat
. 2022 Sep;
22(1):128-142.
PMID: 36163614
The phase II basket trial in oncology is a novel design that enables the simultaneous assessment of treatment effects of one anti-cancer targeted agent in multiple cancer types. Biomarkers could...
4.
Takeda K, Xia Q, Liu S, Rong A
Pharm Stat
. 2021 Dec;
21(2):496-506.
PMID: 34862715
The new therapeutic agents, such as molecular targeted agents and immuno-oncology therapies, appear more likely to induce multiple toxicities at different grades than dose-limiting toxicities defined in traditional dose-finding trials....
5.
Takeda K, Liu S, Rong A
Stat Med
. 2021 Oct;
41(2):298-309.
PMID: 34697822
The basket trial in oncology is a novel clinical trial design that enables the simultaneous assessment of one treatment in multiple cancer types. In addition to the usual basket classifier...
6.
Chu C, Liu S, Rong A
Pharm Stat
. 2020 Jan;
19(4):358-369.
PMID: 31930622
In the traditional study design of a single-arm phase II cancer clinical trial, the one-sample log-rank test has been frequently used. A common practice in sample size calculation is to...
7.
Li W, Chen S, Rong A
J Biopharm Stat
. 2018 Oct;
29(2):229-243.
PMID: 30359557
In randomized controlled trials with delayed treatment effect, there is a delay period before the experimental therapy starts to exhibit a beneficial effect. The phenomenon of delayed treatment effect is...
8.
Liu S, Chu C, Rong A
Pharm Stat
. 2018 Jul;
17(5):541-554.
PMID: 30058101
A cancer clinical trial with an immunotherapy often has 2 special features, which are patients being potentially cured from the cancer and the immunotherapy starting to take clinical effect after...
9.
Diao G, Dong J, Zeng D, Ke C, Rong A, Ibrahim J
J Biopharm Stat
. 2018 Feb;
28(6):1038-1054.
PMID: 29436940
Due to the importance of precision medicine, it is essential to identify the right patients for the right treatment. Biomarkers, which have been commonly used in clinical research as well...
10.
Gao F, Dong J, Zeng D, Rong A, Ibrahim J
Stat Med
. 2017 May;
36(19):2994-3004.
PMID: 28464562
Targeted therapies for cancers are sometimes only effective in a subset of patients with a particular biomarker status. In clinical development, the biomarker status is typically determined by an investigational-use-only/laboratory-developed...